Abstract：
OBJECTIVE: To assess the efficacy of microneedling in combination with topical tacrolimus ointment 0.1% versus topical tacrolimus ointment 0.1% for treatment of refractory stable vitiligo.
METHODS: Comparative cross-sectional study. Place and Duration of the Study: Department of Dermatology, PNS Shifa, Karachi, Pakistan, from December 2022 to May 2023.
METHODS: The study included 30 clinically diagnosed individuals of either gender who had refractory symptoms and aged between 20 and 60 years. For every patient, two comparable lesions on two comparable limb regions were selected. Group A (right side) received treatment with both topical tacrolimus ointment 0.1% twice daily in addition to microneedling every two weeks, whereas, Group B (left side) was treated with topical tacrolimus ointment 0.1% only. Every lesion was investigated as a separate entity. Both groups were subsequently observed for a further six months.
RESULTS: When topical tacrolimus ointment 0.1% was combined with microneedling, the total re-pigmentation rate was substantially higher than the usage of tacrolimus ointment 0.1% alone. Fifty-three percent of lesions treated with topical tacrolimus ointment 0.1% alone and 76.7% of lesions treated with microneedling in conjunction with it showed a good-to-excellent response. No adverse negative effects were noted. During the follow-up period, no problems or recurrences were noted.
CONCLUSIONS: Tacrolimus ointment combined with microneedling is a successful treatment for refractory stable vitiligo.
BACKGROUND: Dermapen, Depigmentation, Microneedling, Tacrolimus ointment, Vitiligo.
METHODS: Comparative cross-sectional study. Place and Duration of the Study: Department of Dermatology, PNS Shifa, Karachi, Pakistan, from December 2022 to May 2023.
METHODS: The study included 30 clinically diagnosed individuals of either gender who had refractory symptoms and aged between 20 and 60 years. For every patient, two comparable lesions on two comparable limb regions were selected. Group A (right side) received treatment with both topical tacrolimus ointment 0.1% twice daily in addition to microneedling every two weeks, whereas, Group B (left side) was treated with topical tacrolimus ointment 0.1% only. Every lesion was investigated as a separate entity. Both groups were subsequently observed for a further six months.
RESULTS: When topical tacrolimus ointment 0.1% was combined with microneedling, the total re-pigmentation rate was substantially higher than the usage of tacrolimus ointment 0.1% alone. Fifty-three percent of lesions treated with topical tacrolimus ointment 0.1% alone and 76.7% of lesions treated with microneedling in conjunction with it showed a good-to-excellent response. No adverse negative effects were noted. During the follow-up period, no problems or recurrences were noted.
CONCLUSIONS: Tacrolimus ointment combined with microneedling is a successful treatment for refractory stable vitiligo.
BACKGROUND: Dermapen, Depigmentation, Microneedling, Tacrolimus ointment, Vitiligo.
摘要：
目的：评估微针疗法联合0.1%外用他克莫司软膏与0.1%外用他克莫司软膏治疗难治性稳定期白癜风的疗效。
方法：比较横断面研究。研究的地点和持续时间：皮肤科，PNSShifa,卡拉奇,巴基斯坦,从2022年12月到2023年5月。
方法：该研究包括30名临床诊断的个体，这些个体具有难治性症状，年龄在20至60岁之间。对每个病人来说,在两个类似的肢体区域选择了两个类似的病变.A组（右侧）除了每两周进行微针治疗外，还接受了0.1％的他克莫司软膏治疗，每天两次，然而,B组(左侧)仅用0.1%的他克莫司软膏治疗。每个病变都作为单独的实体进行研究。两组随后再观察6个月。
结果：当局部用0.1%他克莫司软膏与微针结合使用时，总的再色素沉着率显著高于单独使用0.1%他克莫司软膏。单独使用他克莫司软膏治疗的53％的病变占0.1％，与微针结合治疗的病变占76.7％，表现出良好至优异的反应。没有注意到不良的负面影响。在后续期间,没有发现问题或复发。
结论：他克莫司软膏联合微针治疗难治性稳定期白癜风是一种成功的治疗方法。
背景：Dermapen，脱色,Microneedling,他克莫司软膏,白癜风。
方法：比较横断面研究。研究的地点和持续时间：皮肤科，PNSShifa,卡拉奇,巴基斯坦,从2022年12月到2023年5月。
方法：该研究包括30名临床诊断的个体，这些个体具有难治性症状，年龄在20至60岁之间。对每个病人来说,在两个类似的肢体区域选择了两个类似的病变.A组（右侧）除了每两周进行微针治疗外，还接受了0.1％的他克莫司软膏治疗，每天两次，然而,B组(左侧)仅用0.1%的他克莫司软膏治疗。每个病变都作为单独的实体进行研究。两组随后再观察6个月。
结果：当局部用0.1%他克莫司软膏与微针结合使用时，总的再色素沉着率显著高于单独使用0.1%他克莫司软膏。单独使用他克莫司软膏治疗的53％的病变占0.1％，与微针结合治疗的病变占76.7％，表现出良好至优异的反应。没有注意到不良的负面影响。在后续期间,没有发现问题或复发。
结论：他克莫司软膏联合微针治疗难治性稳定期白癜风是一种成功的治疗方法。
背景：Dermapen，脱色,Microneedling,他克莫司软膏,白癜风。
